Fibrillex on fast track to ’05 filing
This article was originally published in Pharmaceutical Approvals Monthly
Neurochem hopes to complete Phase II/III clinical trial for its fast-track drug candidate Fibrillex by January 2005, with a subsequent 2005 NDA submission. The two-year, randomized, double-blind, placebo-controlled, parallel-design study in secondary amyloid A amyloidosis is ongoing. Fibrillex is a glycosaminoglycan mimetic that treats AA amyloidosis by preventing amyloid fibril formation...
You may also be interested in...
A new analysis of the ADAURA study shows that Tagrisso’s disease-free survival benefits in early stage EGFRm NSCLC are replicated for brain metastases, a common complication with a poor prognosis. Filings and OS data await.
FDA has heard from some manufacturers that additional time is needed to meet all of the requirements, “especially during the COVID-19 pandemic.” Prior to the pandemic, agency announced enforcement discretion during 2020 for compliance by firms with more than $10m in annual sales.
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.